Edoxaban Dosing Regimens Evaluated for AF-Related Stroke
The comprehensive net clinical outcomes of low- and high-dose edoxaban was evaluated for stroke in atrial fibrillation.
The comprehensive net clinical outcomes of low- and high-dose edoxaban was evaluated for stroke in atrial fibrillation.
The study authors analyzed the association of atrial fibrillation recurrence with heart failure, atrial fibrillation burden, and clinical outcomes in HF patients with AF.
Study authors evaluated whether using an observational study that includes Medicare claims data could detect the proarrhythmic risk of medications known to prolong the QT interval.
Risks for ischemic stroke or systemic embolism, major bleeding events lower with DOACs overall as a class versus warfarin.
Dual antithrombotic therapy is now the ‘default’ regimen, with triple therapy reserved for patients who may benefit it after carefully assessing risk-benefit ratio.
This European study evaluated the relationship between alcohol consumption, cardiac biomarkers, and incident atrial fibrillation across the spectrum of alcohol intake.
This meta-analysis aimed to determine the association between SGLT2i use and arrhythmias in patients with T2DM or HF.
Remote PAP-guided management better reduced PAP, hospitalizations, and mortality among patients with NYHA Class III HF.
The authors reported that 25 of the total 233 patients included in the study experienced a bleeding event.
Deep neural networks using information from a12-lead ECG can predict new-onset atrial fibrillation (AF) risk in patients with no prior history of AF.